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Parenteral aluminum administration in the dog: II. Induction of
osteomalacia and effect on vitamin D metabolism. There is an association
between bone aluminum (Al) accumulation and dialysis-associated
osteomalacia (OM). To study whether Al is pathogenic in OM, quantita-
tive bone histomorphometry was done in six dogs before (Bx I) and
after (Bx 2) 3 to 5 weeks of intravenous Al administration (1 mg
Al k/kg/day). Bone Al was determined by histochemical and chemical
methods. The percent osteoid rose from 2.8 0.8 to 7.0 4.3% (mean
SD), P <0.05, and osteoid width increased from 5.7 0.6 to 8.0 1.2
, P <0.01, after Al. Bone Al rose from 1.3 1.6 to 94.0 19.0 mg/kg
after Al, and the severity of OM, expressed as either percent forming
surface or percent osteoid, correlated with bone Al measured histo-
chemically and expressed as either percent surface or percent area of
trabecular bone staining for Al (r = 0.85 — 0.90, P <0.01). Poor
tetracycline uptake (six dogs), which indicates impaired mineralization,
and little or no separation of tetracycline labels (four dogs) were noted
at Bx 2; thus, bone apposition and formation rates were below the limits
of detection. Resorptive surface did not change but trabecular volume,
expressed as percent of tissue volume, fell from 22.1 3.0 to 17.1
l.4%,P<0.05. Serum levels of l,25(OH)2Dfell from 26.8 9.1 to4.5
5.5 pg/mI after 17 days of Al; serum 25(OH)D levels were unchanged.
These data indicate that Al can cause OM and that its seventy
correlates with the bone Al content. These findings suggest that Al has a
direct effect on bone; the role of altered vitamin D metabolism in
mediating these changes remains to be defined.
Administration parentérale d'aluminium chez le chien: II. Induction
d'une ostéomalacie et effet sur le métabolisme de Ia vitamine D. Ii existe
une association entre l'accumulation d'aluminium osseux (Al) et l'os-
téomalacie associée a l'hemodialyse. Afin d'étudier si Al a un role
pathogene dans OM, une histomorphométrie osseuse quantitative a eté
effectuée chez six chiens avant (Bx I) et aprés (Bx 2) 3 a 5 semaines
d'administration intraveineuse d'Al (1 mg AU'/kg/jour). L'Al osseux
a été déterminé par des méthodes histochimiques et chimiques. Le
pourcentage d'ostéoIde s'est élevé de 2,8 0,8 a 7,0 4,3% (moyenne
SD), P < 0,05, et l'épaisseur ostéoIde s'est ciii de 5,7 0,6 a 8,0 1,2
p., P < 0,01, après Al. L'Al osseux a augmenté de 1,3 1,6 a 94,0
19,0 mg/kg aprés Al, et Ia sévérité de l'OM, exprimée soit en pourcen-
tage de surface en formation, soit en pourcentage d'ostéoIde, était
corrélée avec l'Al osseux mesuré histochimiquement et exprimé soit en
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pourcentage de surface, soit en pourcentage d'aire d'os trabéculaire
donnant une coloration pour l'Al (r = 0,85 — 0,90, P < 0,01). Une faible
fixation de tetracycline (six chiens) ce qui indique une anomalie de
minéralisation, ou une faible ou l'absence de separation des marquages
par Ia tetracycline (quartre chiens) ont eté notees a Bx 2; ainsi, les
vitesses d'apposition et de formation osseuses étaient en dessous des
limites de detection. La surface de resorption n'a pas change, mais Ic
volume trabéculaire, exprimé en pourcentage du volume tissulaire, a
diminuéde22,1 3,0a17,1 1,4%,P<0,05. Lesniveauxseriquesde
1,25(OH)2D ont baissé de 26,8 9,1 a 4,5 5,5 pg/mI après l7jours
d'Al; les concentrations sériques de 25(OH)D étaient inchangees. Ces
données indiquent qu'Al peut entrainer une OM dont Ia sévérité est
correlée au contenu osseux en Al. Ces résultats suggèrent qu'Al a un
effet direct sur l'os; le role de l'altération du métabolisme de Ia vitamine
D dans ces modifications reste a determiner.
A growing body of evidence suggests an association between
the syndrome "dialysis-related osteomalacia" and the accumu-
lation of aluminum in bone. Several clinical studies have
indicated a high incidence of fracturing bone disease in patients
undergoing hemodialysis with water containing aluminum [1—
4]. A high bone aluminum content has been demonstrated by
both chemical and histochemical techniques in many dialysis
patients, a substantial portion of whom show histologic evi-
dence of osteomalacia 15—9]. Furthermore, the severity of
osteomalacia, as assessed by the degree of osteoid accumula-
tion, correlates positively with the aluminum content of bone
[6, 7, 10]. A recent report suggests that aluminum deposition in
bone can occur early in the course of clinical dialysis-associated
osteomalacia, perhaps antedating overt histological changes [8].
It is possible that the passive uptake of aluminum by poorly
or unmineralized osteoid might account for the associations
described. The kidney is the major route for the excretion of
aluminum [11], and it is not unexpected that patients with
markedly reduced renal function might retain aluminum. In-
deed, bone is one of the primary tissues in which aluminum
accumulates in the presence of renal insufficiency [12].
Few experimental studies have evaluated the potential for
bone toxicity of aluminum or its relationship to the pathogene-
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Fig. 1. Quantitative histomorphometric data and dynamic histology in six dogs loaded with aluminum for three (dogs 1 and 2) or 5 weeks. The
brackets are the mean SD of normal values obtained in four separate female dogs. The apposition rates after aluminum loading were calculated
only in the four dogs that received double tetracycline labeling before the second biopsy was performed. Abbreviations are: C, control biopsy; Al,
after aluminum loading. Individual numbered dogs are represented by the following symbols: 1, •; 2, 0; 3, X; 4, U; 5, 6, 0. The asterisks repre-
sent values that differ from control: *, P < 0.05; **, P < 0.01.
sis of osteomalacia. Ellis, McCarthy, and Hernngton [9] de-
scribed defective mineralization in the tibial epiphyses of rats
given intraperitoneal aluminum injections for as long as 105
days. The mineralization of newly forming bone became normal
after the administration of aluminum was stopped. Two other
reports indicate that aluminum loading can induce osteomalacic
changes in the trabecular bone of rats [13, 141. In one study this
occurred only in uremic animals (14], whereas in the other, both
uremic and nonuremic rats were affected (13].
To investigate the effect of aluminum administration on bone,
quantitative bone histomorphometry was done in dogs given
daily parenteral aluminum injections for 3 to 5 weeks. In
addition, serial serum levels of 25-hydroxyvitamin D [25(OH)D]
and l,25-dihydroxyvitamin-D [1,25(OH)2D] were measured.
Methods
Six female mongrel dogs weighing 18 to 34 kg were studied.
Animals were maintained on standard laboratory dog chow
(Ralston Purina, St. Louis, Missouri) for the duration of study.
All dogs received bolus intravenous injections of aluminum
chloride containing 1 mglkg elemental aluminum 5 days each
week. Four dogs received injections of aluminum for S weeks;
the injections were terminated after 3 weeks in two dogs.
Serum levels of calcium, phosphorus, 25(OH)D, and
l,25(OH)2D were measured by methods reported elsewhere [15,
16] in blood specimens obtained twice weekly in the fasting
state prior to the daily aluminum injection. The content of
aluminum was measured in trabecular bone samples as reported
elsewhere [17]. The detailed results of serum levels of calcium,
immunoreactive parathyroid hormone (iPTH), and aluminum,
serial measurements of renal function, and the results of kinetic
studies of aluminum are reported elsewhere [18]. The animals
underwent bone biopsy prior to and after 3 to 5 weeks of
parenteral aluminum loading. For the initial bone biopsy,
double tetracycline labelling of bone was achieved by the oral
administration of tetracycline hydrochloride (30 mg/kg) for 3
consecutive days followed by a second course of tetracycline,
also of 3 days duration, after an interlabel period of 18 days
duration. Because renal function declined after aluminum ad-
ministration, the second bone biopsy was done earlier than
planned. Thus, the double tetracycline labelling was carried out
with an interval of only 6 days between the "labels" in four
dogs. In the other two animals, terminated after 3 weeks of
aluminum injections, only a single course of tetracycline of 2
days duration was given before the second biopsy. For all
biopsies, the bone specimen was obtained 24 hr after the last
dose of tetracycline.
The bone biopsy specimens were fixed for 24 hr in phosphate-
buffered formalin and dehydrated by sequential passage
through 70 and 90% ethanol, for 24 hr each, Final dehydration
was achieved by three changes in 100% ethanol, each of 24 hr.
Specimens were infiltrated with methylmethacrylate for 24 hr at
room temperature and then polymerized at 35°C in a drying
oven for 24 hr. The blocks were trimmed and both 5- and l0-
sections of nondecalcified bone were made with a microtome
(Model 1140, Autocut Reichert-Jung, Vienna, Austria). Five-
micron sections for light microscopy were stained using the
modified technique of Goldner as described in detail elsewhere
[19] and mounted in Protex. For the evaluation of tetracycline
fluorescent labels, unstained l0-j sections were mounted in
10% glycerol. Five-micron sections were stained for aluminum
according to the method of Maloney et al [6].
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Light microscopy was accomplished using a Leitz micro-
scope equipped with both tungsten and halogen light sources.
Fluorescent microscopy was performed utilizing a Ploemo-Pak
epiflorescent attachment with a 200-watt mercury light source.
Quantitative bone histology was done using a digitizer (Summa-
graphics Corporation, Fairfax, Connecticut) interfaced with a
series of computerized measuring programs (Model 5110, IBM,
Princeton, New Jersey). Image projection was achieved by
projection prism and drawing tube microscopic attachments.
The transiliac biopsy specimens were obtained from the iliac
bone of all dogs from an area of 1 to 2 cm caudal to the cranial
dorsal spine adjacent to the lateral cortex using the Bordier
biopsy needle; this site was selected according to the report of
Hardt and Jee [20]. In addition to the six dogs given aluminum,
four female mongrel dogs not involved in the present investiga-
tion also underwent bone biopsy at this site. Quantitative
histomorphometry was also carried out on these specimens.
The variance among a minimum of six sections from each of
these four biopsy specimens was analyzed for each static
histological parameter measured. The mean coefficient of varia-
tion was less than 10% for all measurements with the exception
of resorption surface, which was 12%.
The histologic variables for trabecular bone, determined from
a minimum of three sections of bone from each biopsy, included
(1) total bone area (%)—the area of trabecular bone, including
both mineralized bone and osteoid, expressed as a percentage
of the total tissue area; (2) osteoid area (%)—the measured area
of osteoid expressed as a percent of the total bone area; (3)
forming surface (%)—the percent of total trabecular surface
covered by osteoid seams; (4) resorbing surface (%)—the
percent of the trabecular surface characterized by the presence
of scalloped bone resorbing surfaces; and (5) osteoid width
(microns)—the mean width of surface osteoid seams, calculated
by dividing the measured osteoid area, in square millimeters, by
the length, in millimeters, of the osteoid seams. Bone apposi-
tion rate was calculated from the mean width of separation of
the tetracycline labels divided by the time interval between
labels; this is expressed in microns/day.
Unless otherwise noted, all values are expressed as the mean
SE. Statistical analysis of the data employed Student's t test
for paired samples and linear regression analysis.
Results
Sequential bone biopsies performed following the parenteral
administration of aluminum demonstrated the development of
changes consistent with histologic osteomalacia (Fig. 1). Both
percent osteoid and osteoid width increased significantly from
the first to the second biopsy in all dogs. The extent of
trabecular bone surface covered by osteoid rose in four of six
animals, but the overall change from 24.2 3.4 to 37.2 2 1.2%
was not significant. However, dogs 3 and 4 exhibited substan-
tial increments in percent-forming surface; they also showed
the greatest accumulation of aluminum in bone (see below).
There was a virtual arrest of bone formation at the time of the
second biopsy. Tetracycline uptake was patchy and noncontig-
uous at the bone-forming surfaces of all six dogs. In the four
dogs with double tetracycline labeling before the second biop-
sy, only occasional sites of double tetracycline label were
identified beneath surface osteoid seams. Because sufficient
double tetracycline labeling of bone could not be identified,
neither bone apposition rates nor bone formation rates could be
calculated in the four dogs given double tetracycline labels after
the period of aluminum administration.
The percent of trabecular resorption surface was unchanged
from the first to the second biopsy (Fig. 1). However, trabecu-
lar bone area, expressed as the percent of total tissue area,
decreased (P <0.05).
The trabecular bone content of aluminum, determined by
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Fig. 2. Correlations between bone aluminum
content, determined by quantitative
histomorphometry and expressed as both
percent of trabecular surface and percent of
trabecular bone area staining for aluminum,
and the degree of osteoid accumulation after
aluminum loading (second biopsy). The
symbols used are the same as those in Figure
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fell from 26.8 3.7 pg/ml during the control period to 12.4 3.7
and 6.9 1.6 pg/mI at 10 and 17 days, P < 0.05 and <0.01,
respectively (Fig. 3). The levels of l,25(OH)2D fell to undetect-
able levels (less than 5 pg/ml) in four of six dogs after 2 weeks of
aluminum administration.
Discussion
The results of the present investigation clearly indicate that
short-term parenteral aluminum administration can cause overt
histological osteomalacia in the dog. As documented by an
increase in the percentage of unmineralized bone matrix and
widened osteoid seams, osteoid accumulation is a hallmark of
osteomalacia. The failure to detect substantial tetracycline
uptake at bone-forming surfaces at the time the second biopsy
was performed also indicates both diminished bone apposition
— and mineralization, characteristic features of osteomalacia [211.
These findings in the dog support previous observations in the
______________
rat which suggest that aluminum loading can cause osteomala-
cia in trabecular bone 19, 13, 14].
Several clinical reports and histological studies of bone have
indicated an association between the accumulation of aluminum
in bone and dialysis-associated osteomalacia [5—10]. The results
of the current investigation indicate that the retention of alumi-
num in bone is a factor in the pathogenesis of this syndrome.
The positive correlations between the aluminum content of
bone, as determined by quantitative histology, and the severity
of histologic osteomalacia are analogous to results described in
clinical material [5, 6, 10]. The impairment of renal function in
the present dogs, described in detail elsewhere [181, was only
moderate until very near the end of the study in three dogs. The
histomorphological features of bone in the present study differ
markedly from those of the conventional osteitis fibrosa ob-
served in chronic renal failure [19]; thus, it is unlikely that renal
failure contributed to the bone disease observed, other than by
impairing the ability of the animals to excrete aluminum.
Despite the strength of the epidemiologic observations show-
ing an association between aluminum accumulation in bone and
the presence of osteomalacia, such observations could also be
explained by the passive accumulation of aluminum within
unmineralized osteoid. The present observations clearly ex-
clude this as an explanation based on the documentation of
normal bone histology and the absence of aluminum in bone
prior to aluminum loading.
The source and time frame of aluminum exposure as well as
the dosage of aluminum are clear in the present study, unlike
the situation with most clinical observations of dialysis osteo-
malacia. The magnitude of the osseous changes observed within
such a short period was unexpected. These findings indicate
that relatively short-term exposure to large doses of aluminum
can produce osteomalacia. Whether it is the high plasma level
of aluminum present or the aluminum accumulation along bone-
forming surfaces that mediates this disorder is not resolved by
the present data. The preponderance of aluminum detected at
the trabecular bone surfaces by histochemical stain in the
present study is consistent with previous observations reported
in clinical biopsy material [6, 22]. Moreover, results using the
electron microprobe to localize aluminum deposition in bone
confirm the surface localization of aluminum at the mineraliza-
tion front of bone following aluminum exposure [5, 22]. Taken
together, these observations are consistent with the local sur-
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Fig. 3. Serum levels of 1,25(OH)2D in six dogs before and after
aluminum loading (1 mg Al /kg intravenously five times per week).
Control (C) values represent the mean of three to five determinations in
each animal. The brackets encompass the mean SD for all control
values. Dogs 1 and 2 received aluminum for 3 weeks only. The
remaining symbols used are the same as those in Figure 1.
flameless atomic absorption spectroscopy, increased from 1.3
1.6 to 94 19 mg/kg dry weight following aluminum loading.
Histochemical staining for aluminum revealed no aluminum in
bone samples obtained prior to aluminum administration,
whereas all bone specimens demonstrated positive staining at
the time of second biopsy. The extent of aluminum accumula-
tion in bone, measured histochemically, correlated with the
severity of osteomalacia, as determined by both the percent of
osteoid and the percent of trabecular-forming surface (Fig. 2).
This was true whether bone aluminum was expressed as the
percentage of trabecular surface staining positive for aluminum
or as the percent of trabecular bone area which exhibited
aluminum staining.
There were substantial changes in serum biochemical param-
eters and reductions in renal function, particularly during the
later part of the course of aluminum administration; these data
are reported in detail elsewhere [18]. To summarize briefly,
hypercalcemia developed in five of six dogs and became
marked in three animals during the few days before the studies
were terminated. Also, renal function decreased in all animals,
with marked changes in four. Despite the increments in serum
calcium, serum iPTH levels were not suppressed in any of the
dogs and actually increased above normal during aluminum
administration in four animals. Serum phosphorus levels were
generally not increased, except when renal function was mark-
edly impaired in two dogs. Persistently low serum phosphorus
levels, with values of 1.6 to 3.5 mg/dl, developed only in dog no.
Serum levels of 25(OH)D were 45 5.5 ng/ml during the
control period and did not change during aluminum administra-
tion. During aluminum loading, there were substantial reduc-
tions in the serum levels of 1,25(OH)2D; thus, the serum values
6.
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face deposition of aluminum as the pathogenic factor. The
return of normal mineralization at the growth plate of rats on
discontinuation of aluminum administration [9] is consistent
with either the increased plasma levels of aluminum or its
surface deposition in bone being responsible for the
abnormality.
Bone apposition and mineralization ceased almost totally in
the six dogs. Similar findings have been noted previously both
in humans [7, 81 and rats loaded with aluminum [13, 14, 23]. A
reduction in PTH secretion has been suggested as one explana-
tion for these results [5, 7, 241. The present observations clearly
indicate that aluminum administration can produce osteomala-
cia in the presence of normal or even increased serum levels of
iPTH. Moreover, observations reported elsewhere in these
dogs indicate that the short-term in vivo administration of
aluminum has little or no effect on PTH secretion [18]. It should
be noted, however, that the present findings do not exclude the
possibility that a reduction in PTH secretion may contribute to
the development of "low turnover" osteomalacia in patients
with prolonged exposure to aluminum.
The current observation of reduced serum levels of
1,25(OH)2D in aluminum-treated dogs is of interest. This oc-
curred in the presence of (1) normal levels of its precursor,
25(OH)D, (2) serum phosphorus values which were generally
normal, and (3) either normal or elevated serum levels of iPTH.
Renal function declined in these animals and low serum levels
of 1 ,25(OH)2D are well documented in advanced renal insuffi-
ciency [25—27]; thus, the observed changes in serum
1 ,25(OH)2D might be explained on the basis of reduced renal
function. Furthermore, the development of hypercalcemia
might be expected to reduce the renal synthesis of l,25(OH)2D,
presumably through the suppression of PTH secretion [28]; no
evidence of reduced parathyroid function was found in the
current study. Moreover, the reduction in the serum levels of
l,25(OH)2D occurred early in the course of the experiments and
prior to the appearance of either a substantial impairment of
renal function or the advent of marked hypercalcemia. Thus,
the present data are most consistent with aluminum having a
direct inhibitory effect on the synthesis of l,25(OH)2D by the
proximal tubule. The kidneys from these dogs showed alumi-
num accumulation that was greater than that in most other
tissues [181, a factor which might contribute to impaired biosyn-
thesis of 1,25(OH)2D.
Some degree of aluminum retention is common with renal
insufficiency [12]; this fact and the present observations also
raise the possibility that the retention of aluminum could be a
factor which contributes to the low serum levels of 1 ,25(OH)2D
in patients with advanced renal failure. This possibility seems
unlikely, however, in that markedly reduced serum levels of
1 ,25(OH)D are observed almost uniformly in patients with
endstage renal failure [25—27], regardless of whether they
exhibit clinical features which suggest aluminum accumulation.
It is possible that the low serum levels of 1,25(OH)2D
observed could have contributed to the development of osteo-
malacia in the dogs in the present study; the present data do not
exclude this possibility. The failure of dialysis osteomalacia to
respond to treatment with 1,25(OH)2D3 [29—3 1] makes it unlike-
ly that altered vitamin D metabolism induced by aluminum is
responsible for the osteomalacia observed clinically. It is also of
interest that low serum levels of 1 ,25(OH)2D have been noted in
patients treated with long-term total parenteral nutrition [15].
Moreover, these patients may exhibit low turnover osteomala-
cia with aluminum accumulation in bone [32—33]. The casein
hydrolysate, which had been used as a protein source in some
TPN solutions, probably provided substantial quantities of
parenteral aluminum to these patients [34]. The present obser-
vations suggest that not only might aluminum be responsible for
impaired mineralization of bone but also raise the possibility
that aluminum could be responsible for the reduced biosynthe-
sis of l,25(OH)2D3 in these patients.
Despite the elevated serum levels of iPTH in four of six
animals in the present study, the trabecular bone from these
dogs showed no increase in the extent of resorptive surface.
This raises the possibility that aluminum might blunt the effect
of PTH to recruit additional osteoclasts. Moreover, there are
data which indicate that increased aluminum levels can reduce
PTH-stimulated alkaline and acid phosphatase activities in the
rat calvaria studied in vitro [35].
The reduction in trabecular bone volume following aluminum
administration in the present experiment was unexpected,
particularly in the absence of any increase in resorptive surface
of bone. This could represent sampling error as a result of
variation at the Site of the iliac bone selected for biopsy.
However, comparisons with values for trabecular bone area
determined in the first biopsy, as well as with those from four
normal dogs excluded from the present study, suggest that the
reduction in bone volume was not an anomalous measurement.
It should be noted that the failure to identify an increase in
resorptive surface does not exclude the presence of an increase
in the cellular activity of osteoclasts at these surfaces. Further-
more, a reduction in bone formation could not account for the
measured decline in trabecular bone volume because of the
short-term nature of the present study. Thus, it is certainly
possible that a substantial increase in cellular activity at bone
resorptive surfaces might account for the reduction in trabecu-
lar volume observed; however, to our knowledge, there are no
data to support or refute this possibility.
The current findings clearly show that the short-term admin-
istration of aluminum can lead to osteomalacia and perhaps
osteopenia in dogs. Impaired release of PTH does not appear to
be a factor in mediating the observed reductions in bone
formation and mineralization. These latter two events appear to
occur, at least partially, as a direct effect of aluminum on bone.
Acknowledgments
Presented, in part, before the 15th Annual Meeting of the American
Society of Nephrology, Chicago, Illinois, December 12—14, 1982. This
work was supported in part by United States Public Health Service
grants AM29926 and AM1475O and research funds from the Veterans
Administration. Dr. R. K. Nudelman is recipient of a Veterans Admin-
istration Associate Investigator award and Drs. A. C. Alfrey and J. W.
Coburn are recipients of Medical Investigator Awards of the Veterans
Administration. Technical assistance was provided by D. Mishler, J.
Gilligan, N. Miller, J. Steppe, and E. Tallos. Secretarial assistance was
provided by A. Sate.
Reprint requests to Dr. J. W. Coburn, Nephrology Section 691/JilL,
Veterans Administration Wadsworth Medical Center, Wilshire and
Sawtelle Blvds., Los Angeles, Calfornia 90073, USA
References
1. PLATTS MM, GOODS GC, HISLOP JS: Composition of the domestic
water supply and the incidence of fractures and encephalopathy in
Aluminum-induced osteomalacia in the dog 375
patients on home dialysis. Br MedJ 2:657—660, 1977
2. WARD MK, FEEST TO, ELLIS HA, PARKINSON IS, KERR DNS:
Osteomalacic dialysis osteodystrophy: evidence for a water-borne
etiological agent, probably aluminum. Lancet 1:841—845, 1979
3. PARKINSON IS, FEEST TO, WARD MK, FAWCETT RWP, KERR
DNS: Fracturing dialysis osteodystrophy and dialysis encephalop-
athy: an epidemiological survey. Lancet 1:406—409, 1979
4. Piuis AM, EDWARDS WG JR, CULLU US JR, MCCALL JT,
ELLIS HA: Hemodialysis encephalopathy with osteomalacic frac-
tures and muscle weakness. Kidney mt 18:115—124, 1980
5. COURNOT-WITMER 0, ZINGRAFF J, PLACHOT JJ, Escia F, LE-
FEVRE R, BOUMATI P, BOURDEAU A, GARABEDIAN M, GALLE P,
BOURDON R, DRIJEKE T, BALSAN S: Aluminum localization in bone
from hemodialyzed patients: Relationship to matrix mineralization.
Kidney tnt 20:376—385, 1981
6. MALONEY NA, OTT S, ALFREY AC, COBURN JW, SHERRARD JD:
Histologic quantitation of aluminum in iliac bone from patients with
renal failure. J Lab C/in Med 99:206—216, 1982
7. HODSMAN AB, SHERRARD DJ, ALFREY AG, 0-ri- S, BRICKMAN AS,
MILLER ML, MALONEY NA, COBURN JW: Bone aluminum and
histomorphometric features of renal osteodystrophy. J C/in Endo-
crinol Metab 54:539—546, 1982
8. OTT SM, MALONEY NA, COBURN JW, ALFREY AC, SHERRARD DJ:
The prevalence of aluminum in renal osteodystrophy and its
relationship to response to calcitriol therapy. N Engi J Med
307:709—713, 1982
9. ELLIS HA, MCCARTHY JH, HERRINGTON J: Bone aluminum in
hemodialysed patients and in rats injected with aluminum chloride:
relationship to impaired bone mineralization. J C/in Pathol 32:832—
844, 1979
10. COURNOT-WITMER B, ZINGRAFF J, BOURDON R, DRUEKE T,
BALSAN S: Aluminum and dialysis bone disease (letter). Lancet
2:795—796, 1979
11. KOVALCHIK MT, KAEHNY WD, HEGG AP, JACKSON JT, ALFREY
AL: Aluminum kinetics during hemodialysis. J Lab C/in Med
92:712—720, 1978
12. ALFREY AC, HEGG A, CRASWELL P: Metabolism and toxicity of
aluminum in renal failure. Am J C/in Nur 33:1509—15 16, 1979
13. ROBERTSON JA, FELSENFELD AJ, HAY000D CC, WILSON P,
CLARKE C, LLACH F: An animal model of aluminum induced
osteomalacia: Role of chronic renal failure. Kidney tnt 23:327—335,
1983
14. CHAN Y, ALFREY AC,POSEN 5, LISSNERD, HILLS E, DUSTANCR,
EVANS RA: The effect of aluminum on normal and uremic rats:
Tissue distribution, vitamin D metabolites and quantitative bone
histology. Ca/cif Tissue tnt 23:344—351, 1983
15. KLEIN GL, H0R5T RL, NORMAN AW, AMENT ME, SLATOPOLSKY
E, COBURN JW: Reduced serum levels of I alpha, 25-dihydroxyvi-
tamin D during long-term total parenteral nutrition. Ann Intern Med
94:638—643, 1981
16. HORST RA, LITTLEDIKE ET, RILEY JL, NAPOLI JL: Quantitation of
vitamin D and its metabolites and their plasma concentrations in
five species of animals. Ann Biochem 116:189—203, 1981
17. LEGENDRE GR, ALFREY AC: Measuring picogram amounts of
aluminum in biological tissue by flameless atomic absorption analy-
sis of a chelate. C/in Chem 22:53—56, 1976
18. HENRY DA, GOODMAN WO, NUDELMAN RK, DIDOMENICO ND,
ALFREY AC, SLATOPOLSKY E, STANLEY TM, COBURN JW: Paren-
teral aluminum administration in the dog: I. Plasma kinetics, tissue
levels, calcium metabolism, and parathyroid hormone. Kidney tnt
25:362—369, 1984
19. SHERRARD DJ, BAYLINK DJ, WERGEDAL JE, MALONEY NA:Quantitative histological studies on the pathogenesis of uremic
bone disease. J C/in Endocrino/ Metab 39:119—135, 1974
20. HARDT AB, JEE WSS: Variation of trabecular bone characteristics
in iliac biopsy sites of the beagle dog, in Bone Histomorphometty-
Third Internationa/ Workshop, edited by JEE WSS, PARFITT AM,
Societe Nouvelle de Publications Medicoles et Dentaires, 1980, pp
492—493
21. FRAME B, PARFITT AM: Osteomalacia: Current concepts. Ann
Intern Med 89:966—982, 1978
22. BOYCE BF, FELL OS, ELDER HY, JUNOR BJ, ELLIOT HL, GEAS-
TALL 0, FOGELMAN I, BOYLE IT: Hypercalcemic osteomalacia due
to aluminum toxicity. Lancet 2: 1009—1013, 1982
23. GOODMAN WE: Effects of aluminum on bone dynamics in the rat
(abstract). C/in Res 31:93A, 1983
24. MORRISSEY J, ROTHSTEIN M, MAYOR G, SLATOPOLSKY E: Sup-
pression of parathyroid hormone secretion by aluminum. Kidney
mt 23:699—704, 1983
25. BRUMBAUGH PF, HAUSSLER DH, BRESSLER R, HAUSSLER MR:
Radio-receptor assay for I alpha,25-hydroxyvitamin D3. Science
183:1089, 1974
26. EISMAN JA, HAMSTRA AJ, KREAM BE, DELUCA HF: 1,25-dihy-
droxyvitamin D in biological fluids: A simplified and sensitive
assay. Science 193:1021, 1976
27. LAMBERT PW, DEOREO PB,HOLLIS BW, Fu IY, GINSEERG DJ,
Roos BA: Concurrent measurement of plasma levels of vitamin D3
and five of its metabolites in normal, chronic renal failure, and
anephric humans. JLab Clin Med 98:536—548, 1981
28. HUGHES MR, HAUSSLER MR, WERGEDAL J, BAYLINK DJ, BRUM-
BAUGH PF: Regulation of serum 1 alpha, 25-dihydroxyvitamin D3
by calcium and phosphate in the rat. Science 190:578, 1975
29. COBURN JW, BRICKMAN AS, SHERRARD DJ, SINGER FR, WONG
EGC, BAYLINK DJ, NORMANAW: Renal osteodystrophy and its
relation to vitamin D: Identification of a mineralizing defect in
uremia unrelated to vitamin D, in Endocrinology of Calcium
Metabolism. Proc 6th Parathyroid Conf, Congress Series No. 421.
Amsterdam, Excerpta Medica, 1977, pp 27—32
30. ALVAREZ-UDE F, FEEST TO, WARD MK, PIERIDES AM, ELLIS
AA, PEART KM. SIMPSON W, WEIGHTMAN D, KERR DNS: Hemo-
dialysis bone disease: Correlation between clinical, histologic, and
other findings. Kidney tnt 14:68—73, 1978
31. HODSMAN AB, SHERRARD DJ, WONG EGC, BRICKMAN AD, LEE
DBN, ALFREY AC, SINGER FR, NORMAN AW, COBURN JW:
Vitamin D-resistant osteomalacia in hemodialysis patients lacking
secondary hyperparathyroidism. Ann Intern Med 94:629—637, 1981
32. KLEIN GL, OTT SM, ALFREY AC, SHERRARD DJ, HAZLET TK,
MILLERNL, MALONEY NA, BERQUIST WE, AMENT ME, COBURN
JW: Aluminum as a factor in the bone disease of long-term
parenteral nutrition. Trans Assoc Amer Physicians 95:155—164,
1982
33. OTT SM, MALONEY NA, KLEIN GL, ALFREY AC, AMENT ME,
COBURN JW, SHERRARD DJ: Aluminum is associated with low bone
formation in patients on chronic parenteral nutrition. Ann Intern
Med 98:910—913, 1983
34. KLEIN GL, ALFREYAC, MILLERNL, SHERRARDDJ, HAZLETTK,
AMENT ME, COBURN JW: Aluminum loading during total parenter-
al nutrition. Am J C/in Nutr 35: 1425—1429, 1982
35. LIEBERHERR M, GROSSE B, COURNOT-WITMER G,THIL CL, BAL-
SAN S: In vitro effects of aluminum on bone phosphatases: possible
interaction with bPTH and vitamin D3 metabolites. Calcif Tissue ml
34:280—284, 1982
